Evidence map›Paper›PMID 33305153›Full record

ArticleHepatology communications2020

Modeling Outcomes in Children With Biliary Atresia With Native Liver After 2 Years of Age.

Veena Venkat, Vicky L Ng, John C Magee, Wen Ye, Kieran Hawthorne, Sanjiv Harpavat, Jean P Molleston, Karen F Murray, Kasper S Wang, Nisreen Soufi and 13 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Biliary atresia.Nature reviews. Disease primers · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. In vitro fertilization: an unexpected finding in a cohort of patients with biliary atresia.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 2 countries.

Veena VenkatUPMC Children's Hospital of Pittsburgh Pittsburgh PA.
Vicky L NgHospital for Sick Children University of Toronto Toronto Canada.
John C MageeUniversity of Michigan Hospitals and Health Centers Ann Arbor MI.
Wen YeUniversity of Michigan Hospitals and Health Centers Ann Arbor MI.
Kieran HawthorneArbor Research Collaborative for Health Ann Arbor MI.
Sanjiv HarpavatTexas Children's Hospital Liver Center, Baylor College of Medicine Houston TX.
Jean P MollestonIndiana University-Riley Hospital for Children Indianapolis IN.
Karen F MurrayCleveland Clinic Children's Cleveland OH.
Kasper S WangChildren's Hospital Los Angeles Los Angeles CA.
Nisreen SoufiChildren's Hospital Los Angeles Los Angeles CA.
Lee M BassAnn & Robert H. Lurie Children's Hospital of Chicago Chicago IL.
Estella M AlonsoAnn & Robert H. Lurie Children's Hospital of Chicago Chicago IL.
Jorge A BezerraCincinnati Children's Hospital Medical Center Cincinnati OH.
M Kyle JensenUniversity of Utah School of Medicine Primary Children's Hospital Salt Lake City UT.
Binita M KamathHospital for Sick Children University of Toronto Toronto Canada.
Kathleen M LoomesThe Children's Hospital of Philadelphia Philadelphia PA.
Cara L MackUniversity of Colorado School of Medicine Children's Hospital Colorado Aurora CO.
Philip RosenthalUniversity of California San Francisco San Francisco CA.
Benjamin L ShneiderTexas Children's Hospital Liver Center, Baylor College of Medicine Houston TX.
Robert H SquiresUPMC Children's Hospital of Pittsburgh Pittsburgh PA.
Ronald J SokolUniversity of Colorado School of Medicine Children's Hospital Colorado Aurora CO.
Saul J KarpenEmory University School of Medicine Atlanta GA.ORCID https://orcid.org/0000-0002-3379-7592
Childhood Liver Disease Research Network
University of Michigan · USBaylor College of Medicine · USChildren's Hospital of Los Angeles · USChildren's Hospital of Pittsburgh · USLurie Children's Hospital · USUniversity of Toronto · CAArbor Research Collaborative for Health · USChildren's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · USCleveland Clinic · USEmory University · USPrimary Children's Hospital · USRiley Hospital for Children · USUniversity of California, San Francisco · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Childhood Liver Disease Research Network Data Coordinating CenterU01DK062456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAGEE, JOHN C, MERION, ROBERT M · 2002 to 2019
$36.8M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Childhood Liver Disease Research Network Data Coordinating CenterU24DK062456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHN C MAGEE · 2019 to 2026
$18.9M
Etiology and Treatment of Biliary Atresia and INHU01DK062453 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI RONALD J. SOKOL · 2002 to 2026
$13.5M
NCATS NIH HHS UL1 TR000130NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001872NCATS NIH HHS UL1 TR001878NCATS NIH HHS UL1 TR002378NCATS NIH HHS UL1 TR002535NCRR NIH HHS UL1 RR025014NIDDK NIH HHS P30 DK078392NIDDK NIH HHS U01 DK062436NIDDK NIH HHS U01 DK062445NIDDK NIH HHS U01 DK062453NIDDK NIH HHS U01 DK062456NIDDK NIH HHS U01 DK062466NIDDK NIH HHS U01 DK062470NIDDK NIH HHS U01 DK062481NIDDK NIH HHS U01 DK062497NIDDK NIH HHS U01 DK062500NIDDK NIH HHS U01 DK084536NIDDK NIH HHS U01 DK084538NIDDK NIH HHS U01 DK084575NIDDK NIH HHS U01 DK103135NIDDK NIH HHS U01 DK103140NIDDK NIH HHS U01 DK103149NIDDK NIH HHS U24 DK062456
6 · The paper itself

Abstract

Approximately 50% of infants with biliary atresia (BA) undergoing Kasai portoenterostomy show survival with native liver (SNL) at age 2 years. Predictors of disease progression after age 2 years are unknown, despite estimates of 20%-30% undergoing liver transplant (LT) between age 2 and 18 years. We sought to address this knowledge gap by developing prognostic models in participants of the multicenter prospective National Institutes of Health-supported Childhood Liver Disease Research Network. We extracted 14 clinical and biochemical variables at age 2 years to develop two models for future outcomes: 1) LT or death (LTD) and 2) first sentinel event (SE), either new onset ascites, hepatopulmonary syndrome (HPS), or gastrointestinal (GI) bleed. A total of 240 participants, enrolled between 2004 and 2017, were followed until a median age of 5.1 years (range, 2.0-13.3 years). Of these participants, 38 underwent LT (n = 37) or death (n = 1); cumulative incidence, 23.7% (95% confidence interval [CI], 16.2%-32.0%). Twenty-seven experienced either new-onset ascites (n = 13), HPS (n = 1), or GI bleed (n = 14). One participant had ascites and GI bleed concurrently; cumulative incidence, 21.5% (95% CI, 14.2%-29.8%) by age 10 years. The Cox proportional hazard model predicted risk of LTD, using total bilirubin, albumin, platelet count, and history of either ascites or cholangitis (BA LTD model), with a C-index of 0.88 (range, 0.86-0.89). A cause-specific hazard competing risk model predicted SE using platelet count and gamma glutamyltransferase levels (BA SE model) with a C-index of 0.81 (range, 0.80-0.84). Internal model validity was assessed using Harrell's C-index with cross-validation.

Identifiers

PMID33305153
PMCPMC7706301
OpenAlexW3091497565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.